Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CSLCSLLY +5.27%73 3-Year EPS without NRI Growth Rate is 11.50% as of Dec. 2025, which is 17% below its 10-year median of 13.85. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.38 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,165 Biotechnology companies, CSL ranks worse than 56.39% on this metric.
During the past 12 months, CSL's average EPS without NRI Growth Rate was -33.70% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 11.50% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 6.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 9.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of CSL was 107.80% per year. The lowest was 0.10% per year. And the median was 13.85% per year.
CSL (OTCPK:CSLLY) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
CSL 3-Year EPS without NRI Growth Rate Related Terms
CSLLY vs VRTX, REGN, RVMD: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, CSL's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where CSL's 3-Year EPS without NRI Growth Rate falls into.
CSL 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 11.50% mean?
CSL (CSLLY) has a 3-Year EPS without NRI Growth Rate of 11.50% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CSL and its competitors. This is 17% below median its historical median of 13.85. Over the past decade, CSL's 3-Year EPS without NRI Growth Rate has ranged from 0.10 to 107.80. According to the industry distribution chart, CSL ranks #657 out of 1165 companies in the Biotechnology industry, placing it in the top 56.4%.
Is CSL's 3-Year EPS without NRI Growth Rate too high?
CSL's current 3-Year EPS without NRI Growth Rate of 11.50% is 17% below median its 10-year median of 13.85. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 107.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. CSL's value of 11.50% is 29% below this industry median. Based on the distribution chart, CSL ranks #657 out of 1165 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's 3-Year EPS without NRI Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #657 out of 1165 companies for 3-Year EPS without NRI Growth Rate. This places CSL in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. CSL's value of 11.50% is 29% below this benchmark. Historically, CSL's own 3-Year EPS without NRI Growth Rate has ranged from 0.10 to 107.80 over the past decade. While the company's 10-year median is 13.85 vs. the industry median of 16.20, CSL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,165 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current 3-Year EPS without NRI Growth Rate of 11.50% is 29% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for CSL and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current 3-Year EPS without NRI Growth Rate is 11.50%, which is 17% below median its own 10-year median of 13.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.38, compared to a current price of $22.19 — trading 56% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 11.50%, which is 17% below median its 10-year median of 13.85 and 29% below the Biotechnology industry median of 16.20. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For CSL (CSLLY), the current 3-Year EPS without NRI Growth Rate is 11.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $22.19 is trading 56% below its estimated GF Value™ of $50.38.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
3-Year EPS without NRI Growth Rate: 11.50% (17% below median its 10-year median of 13.85)
GF Value™: $50.38 vs. price of $22.19 (56% below fair value)
Industry Position: 29% below the Biotechnology median (#657 of 1165)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
